Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.78 |
| ▸ | BCL2 | P10415 | 14/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20305899 | 0.92 | BCL2L1 (0.66) | BCL2L1BCL2 | |
| SCHEMBL28475392 | 0.90 | BCL2L1 (0.79) | BCL2L1BCL2 | |
| SCHEMBL28475394 | 0.90 | BCL2L1 (0.79) | BCL2L1BCL2 | |
| SCHEMBL19263461 | 0.90 | BCL2L1 (0.84) | BCL2L1BCL2BAD | |
| SCHEMBL25963424 | 0.89 | BCL2L1 (0.78) | BCL2L1BCL2 | |
| SCHEMBL554094 | 0.88 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL30777653 | 0.88 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL554095 | 0.88 | BCL2L1 (1.00) | BCL2L1BCL2 | |
| SCHEMBL25423839 | 0.85 | BCL2L1 (0.94) | BCL2L1BCL2 | |
| SCHEMBL10058370 | 0.85 | BCL2L1 (0.74) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004735-B2 | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines | MTOR, ULK2, TTK | BCL2L1 2261/4885BCL2 941/4885BAD 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.